1. Academic Validation
  2. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution

Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution

  • Nucl Med Biol. 2017 Aug:51:1-9. doi: 10.1016/j.nucmedbio.2017.04.005.
Sara Westrøm 1 Roman Generalov 2 Tina B Bønsdorff 3 Roy H Larsen 4
Affiliations

Affiliations

  • 1 Oncoinvent AS, Oslo, Norway; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • 2 Nordic Nanovector ASA, Oslo, Norway.
  • 3 Oncoinvent AS, Oslo, Norway.
  • 4 Oncoinvent AS, Oslo, Norway; Sciencons AS, Oslo, Norway. Electronic address: royhlars1@yahoo.no.
Abstract

Introduction: Alpha-emitting radionuclides have gained considerable attention as payloads for Cancer targeting molecules due to their high cytotoxicity. One attractive radionuclide for this purpose is 212Pb, which by itself is a β-emitter, but acts as an in vivo generator for its short-lived α-emitting daughters. The standard method of preparing 212Pb-labeled Antibodies requires handling and evaporation of strong acids containing high radioactivity levels by the end user. An operationally easier and more rapid process could be useful since the 10.6h half-life of 212Pb puts time constraints on the preparation protocol. In this study, an in situ procedure for antibody labeling with 212Pb, using a solution of the generator nuclide 224Ra, is proposed as an alternative protocol for preparing 212Pb-radioimmunoconjugates.

Methods: Radium-224, the generator radionuclide of 212Pb, was extracted from its parent nuclide, 228Th. Lead-212-labeling of the TCMC-chelator conjugated monoclonal antibody trastuzumab was carried out in a solution containing 224Ra in equilibrium with progeny. Subsequently, the efficiency of separating the 212Pb-radioimmunoconjugate from 224Ra and other unconjugated daughter nuclides in the solution using either centrifugal separation or a PD-10 desalting size exclusion column was evaluated and compared.

Results: Radiolabeling with 212Pb in 224Ra-solutions was more than 90% efficient after only 30min reaction time at TCMC-trastuzumab concentrations from 0.15mg/mL and higher. Separation of 212Pb-labeled trastuzumab from 224Ra using a PD-10 column was clearly superior to centrifugal separation. This method allowed recovery of approximately 75% of the 212Pb-antibody-conjugate in the eluate, and the remaining amount of 224Ra was only 0.9±0.8% (n=7).

Conclusions: The current work demonstrates a novel method of producing 212Pb-based radioimmunoconjugates from a 224Ra-solution, which may be simpler and less time-consuming for the end user compared with the method established for use in clinical trials of 212Pb-TCMC-trastuzumab.

Keywords

(212)Pb; Lead-212; Radioimmunoconjugate; Radium-224; TCMC-trastuzumab; Targeted alpha therapy.

Figures
Products